Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 37

Sort by

Sort Order Select

Meeting Abstracts

776-P: Potent Weight Loss and Favorable Glycemic Control Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Animal Models

SANG HYUN PARK, YOHAN KIM, JUNG KUK KIM, DAHAE LEE, EUNJIN PARK, JEONG A. KIM, SUNGHEE HONG, JAEHYUK CHOI, SUNGMIN BAE, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2024;73(Supplement_1):776-P

https://doi.org/10.2337/db24-776-P

Published: 14 June 2024

View articletitled, 776-P: Potent Weight Loss and Favorable Glycemic Control Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Animal Models

Meeting Abstracts

799-P: Nephroprotective Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Preclinical Models of Acute and Chronic Kidney Diseases

SEON MYEONG LEE, EUNJIN PARK, JUNG KUK KIM, HYE REYEON KANG, JEONG A. KIM, YOHAN KIM, SUNGHEE HONG, SUNGMIN BAE, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2024;73(Supplement_1):799-P

https://doi.org/10.2337/db24-799-P

Published: 14 June 2024

View articletitled, 799-P: Nephroprotective Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Preclinical Models of Acute and Chronic Kidney Diseases

Meeting Abstracts

798-P: Potential Cardioprotective Effects of HM15275, a Novel, Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Hypertension

SEON MYEONG LEE, JUNG KUK KIM, EUNJIN PARK, HYE REYEON KANG, JEONG A. KIM, YOHAN KIM, SUNGHEE HONG, SUNGMIN BAE, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2024;73(Supplement_1):798-P

https://doi.org/10.2337/db24-798-P

Published: 14 June 2024

View articletitled, 798-P: Potential Cardioprotective Effects of HM15275, a Novel, Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Hypertension

Meeting Abstracts

1872-LB: Therapeutic Potential of HM15275, a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Heart Failure

BYEONGJIN YE, WONKI KIM, SEON MYEONG LEE, JEONG A. KIM, EUNSEON KIM, SUNGMIN BAE, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2024;73(Supplement_1):1872-LB

https://doi.org/10.2337/db24-1872-LB

Published: 14 June 2024

View articletitled, 1872-LB: Therapeutic Potential of HM15275, a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Heart Failure

Meeting Abstracts

401-P: Effects of Teneligliptin on Lipotoxicity in High-Fat Diet–Induced Diabetic Kidney Disease Model

HAE KYUNG KIM, RYEONG-HYEON KIM, YURIM YANG, HYUNKI PARK, NARA JEON, MINYOUNG LEE, HYANGKYU LEE, BEOM JIN LIM, HOON YOUNG CHOI, EUN SEOK KANG

Diabetes 2023;72(Supplement_1):401-P

https://doi.org/10.2337/db23-401-P

Published: 20 June 2023

View articletitled, 401-P: Effects of Teneligliptin on Lipotoxicity in High-Fat Diet–Induced Diabetic Kidney Disease Model

Meeting Abstracts

385-P: Effects of Ertugliflozin on Podocyte in High-Fat Diet–Induced Diabetic Kidney Disease Model, In Vivo and In Vitro

HAE KYUNG KIM, YOUNGJOON KIM, RYEONG-HYEON KIM, SIWOO LEE, YURIM YANG, HYUNKI PARK, NARA JEON, MINYOUNG LEE, YONG-HO LEE, BONG-SOO CHA, HYANGKYU LEE, BEOM JIN LIM, HOON YOUNG CHOI, EUN SEOK KANG

Diabetes 2022;71(Supplement_1):385-P

https://doi.org/10.2337/db22-385-P

Published: 01 June 2022

View articletitled, 385-P: Effects of Ertugliflozin on Podocyte in High-Fat Diet–Induced Diabetic Kidney Disease Model, In Vivo and In Vitro

Meeting Abstracts

735-P: Direct Anti-Inflammatory and Antifibrotic Effects of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist, HM15211, in Thioacetamide-Induced Mouse Model of Liver Injury and Fibrosis

JUNG KUK KIM, JONG SUK LEE, YOHAN KIM, SEON MYEONG LEE, HYUNJOO KWON, EUNJIN PARK, JAEHYUK CHOI, SUNGMIN BAE, DAEJIN KIM, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2022;71(Supplement_1):735-P

https://doi.org/10.2337/db22-735-P

Published: 01 June 2022

View articletitled, 735-P: Direct Anti-Inflammatory and Antifibrotic Effects of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist, HM15211, in Thioacetamide-Induced Mouse Model of Liver Injury and Fibrosis

Meeting Abstracts

754-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF

SEON MYEONG LEE, JEONG A. KIM, JONG SUK LEE, JUNG KUK KIM, YOUNG-HWAN BAN, JONGSOO LEE, SUNGMIN BAE, DAEJIN KIM, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2022;71(Supplement_1):754-P

https://doi.org/10.2337/db22-754-P

Published: 01 June 2022

View articletitled, 754-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF

Meeting Abstracts

655-P: Multitarget Engagement Effect of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Animal Model of NASH

JUNG KUK KIM, JONG SUK LEE, HYUNJOO KWON, EUNJIN PARK, JONGSOO LEE, SUNGMIN BAE, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2021;70(Supplement_1):655-P

https://doi.org/10.2337/db21-655-P

Published: 01 June 2021

View articletitled, 655-P: Multitarget Engagement Effect of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Animal Model of NASH

Meeting Abstracts

656-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Fibrosis

JUNG KUK KIM, JONG SUK LEE, SEON MYEONG LEE, HYUNJOO KWON, JAEHYUK CHOI, EUNJIN PARK, SUNGMIN BAE, DAEJIN KIM, YOUNG HOON KIM, IN YOUNG CHOI

Diabetes 2021;70(Supplement_1):656-P

https://doi.org/10.2337/db21-656-P

Published: 01 June 2021

View articletitled, 656-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Fibrosis

Meeting Abstracts

657-P: Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders

JONG SUK LEE, JUNG KUK KIM, SEON MYEONG LEE, JAEHYUK CHOI, EUNJIN PARK, DAEJIN KIM, SUNGMIN BAE, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2021;70(Supplement_1):657-P

https://doi.org/10.2337/db21-657-P

Published: 01 June 2021

View articletitled, 657-P: Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders

Meeting Abstracts

658-P: Sustained Glucagon Effect on Cardiovascular Renal and Metabolic Disorders Mediated by a Long-Acting Glucagon Analog, HM15136, in Animal Disease Models

JONG SUK LEE, SEON MYEONG LEE, JUNG KUK KIM, EUNJIN PARK, JONGSOO LEE, DAEJIN KIM, YOUNG HOON KIM, IN YOUNG CHOI

Diabetes 2021;70(Supplement_1):658-P

https://doi.org/10.2337/db21-658-P

Published: 01 June 2021

View articletitled, 658-P: Sustained Glucagon Effect on Cardiovascular Renal and Metabolic Disorders Mediated by a Long-Acting Glucagon Analog, HM15136, in Animal Disease Models

Meeting Abstracts

1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice

JAEHYUK CHOI, JUNG KUK KIM, SEON MYEONG LEE, HYUNJOO KWON, JONGSOO LEE, SUNGMIN BAE, DAEJIN KIM, IN YOUNG CHOI

Diabetes 2020;69(Supplement_1):1830-P

https://doi.org/10.2337/db20-1830-P

Published: 01 June 2020

View articletitled, 1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice

Meeting Abstracts

1804-P: HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice

JUNG KUK KIM, JONG SUK LEE, EUNJIN PARK, JONGSOO LEE, SUNGMIN BAE, DAEJIN KIM, IN YOUNG CHOI

Diabetes 2020;69(Supplement_1):1804-P

https://doi.org/10.2337/db20-1804-P

Published: 01 June 2020

View articletitled, 1804-P: HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice

Meeting Abstracts

1803-P: Antifibrotic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice

JUNG KUK KIM, JONG SUK LEE, HYUNJOO KWON, JONGSOO LEE, DAEJIN KIM, SUNGMIN BAE, SANG HYUN LEE, IN YOUNG CHOI

Diabetes 2020;69(Supplement_1):1803-P

https://doi.org/10.2337/db20-1803-P

Published: 01 June 2020

View articletitled, 1803-P: Antifibrotic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice

Meeting Abstracts

1926-P: Potent Weight Loss Mechanism of a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models of Obesity

JONG SUK LEE, SEON MYEONG LEE, JUNG KUK KIM, JONGSOO LEE, SANG DON LEE, SUNGMIN BAE, DAEJIN KIM, IN YOUNG CHOI

Diabetes 2020;69(Supplement_1):1926-P

https://doi.org/10.2337/db20-1926-P

Published: 01 June 2020

View articletitled, 1926-P: Potent Weight Loss Mechanism of a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models of Obesity

Meeting Abstracts

1925-P: Beneficial Effects of a Novel Long-Acting Glucagon Analog, HM15136, on Obesity and Obesity-Related Metabolic Disorders in Animal Models

JONG SUK LEE, SEON MYEONG LEE, JAEHYUK CHOI, EUNJIN PARK, JONGSOO LEE, SANG DON LEE, SUNGMIN BAE, DAEJIN KIM, IN YOUNG CHOI

Diabetes 2020;69(Supplement_1):1925-P

https://doi.org/10.2337/db20-1925-P

Published: 01 June 2020

View articletitled, 1925-P: Beneficial Effects of a Novel Long-Acting Glucagon Analog, HM15136, on Obesity and Obesity-Related Metabolic Disorders in Animal Models

Meeting Abstracts

109-LB: Potent Weight Loss Mechanism by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models

JONG SUK LEE, JUNG KUK KIM, JINYOUNG KIM, EUNJIN PARK, SANG HYUN LEE, SUNGMIN BAE, IN YOUNG CHOI

Diabetes 2019;68(Supplement_1):109-LB

https://doi.org/10.2337/db19-109-LB

Published: 01 June 2019

View articletitled, 109-LB: Potent Weight Loss Mechanism by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models

Meeting Abstracts

1011-P: Therapeutic Potential of Novel Combination of a Long-Acting Glucagon Analog (HM15136) and Antidiabetic Drugs for the Treatment of Obesity

YOUNG JIN PARK, JONG SUK LEE, JUNG KUK KIM, DAEJIN KIM, YOUNG HOON KIM, YOUNG CHOI IN

Diabetes 2019;68(Supplement_1):1011-P

https://doi.org/10.2337/db19-1011-P

Published: 01 June 2019

View articletitled, 1011-P: Therapeutic Potential of Novel Combination of a Long-Acting Glucagon Analog (HM15136) and Antidiabetic Drugs for the Treatment of Obesity

Meeting Abstracts

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

JULIO ROSENSTOCK, CRISTOBAL MORALES, SR., ULRICH WENDISCH, GEORGE E. DAILEY, III, MICHAEL E. TRAUTMANN, MARCUS HOMPESCH, IN YOUNG CHOI, JAHOON KANG, JOHN A. STEWART, IKE OGBAA, CHRISTOPHER H. SORLI, KUN-HO YOON

Diabetes 2019;68(Supplement_1):1014-P

https://doi.org/10.2337/db19-1014-P

Published: 01 June 2019

View articletitled, 1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Update search

NARROW

Format

Journal

Article Type

Topics

Issue Section

Date

Availability

776-P: Potent Weight Loss and Favorable Glycemic Control Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Animal Models

799-P: Nephroprotective Effects of a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, HM15275, in Preclinical Models of Acute and Chronic Kidney Diseases

798-P: Potential Cardioprotective Effects of HM15275, a Novel, Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Hypertension

1872-LB: Therapeutic Potential of HM15275, a Novel Long-Acting GLP-1/GIP/GCG Triple Agonist, in Animal Models of Heart Failure

401-P: Effects of Teneligliptin on Lipotoxicity in High-Fat Diet–Induced Diabetic Kidney Disease Model

385-P: Effects of Ertugliflozin on Podocyte in High-Fat Diet–Induced Diabetic Kidney Disease Model, In Vivo and In Vitro

735-P: Direct Anti-Inflammatory and Antifibrotic Effects of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist, HM15211, in Thioacetamide-Induced Mouse Model of Liver Injury and Fibrosis

754-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of IPF

655-P: Multitarget Engagement Effect of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Animal Model of NASH

656-P: Antifibrotic Potential of a Novel Long-Acting Glucagon/GIP/GLP-1 Triple Agonist (HM15211) in Preclinical Models of Fibrosis

657-P: Potential Effect of a Novel Combination of GLP-1RA (efpeglenatide) and Long-Acting Glucagon Analog (HM15136) in Animal Models of Metabolic Disorders

658-P: Sustained Glucagon Effect on Cardiovascular Renal and Metabolic Disorders Mediated by a Long-Acting Glucagon Analog, HM15136, in Animal Disease Models

1830-P: Therapeutic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-Induced NASH and Fibrosis Mice

1804-P: HM15211, a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist, Exhibits Anti-inflammatory and Fibrotic Effects in AMLN/TAA–Induced Liver Inflammation and Fibrosis Mice

1803-P: Antifibrotic Effect of a Novel Long-Acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in BDL-Induced Liver Fibrosis Mice

1926-P: Potent Weight Loss Mechanism of a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models of Obesity

1925-P: Beneficial Effects of a Novel Long-Acting Glucagon Analog, HM15136, on Obesity and Obesity-Related Metabolic Disorders in Animal Models

109-LB: Potent Weight Loss Mechanism by a Novel Long-Acting Glucagon Analog, HM15136, in Animal Models

1011-P: Therapeutic Potential of Novel Combination of a Long-Acting Glucagon Analog (HM15136) and Antidiabetic Drugs for the Treatment of Obesity

1014-P: Relationship between Glycemic Control and Weight Loss with Once-Weekly Efpeglenatide in Uncontrolled Type 2 Diabetes: A Subanalysis of EXCEED 203

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Update search

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only